1. Home
  2. AGIO vs BAK Comparison

AGIO vs BAK Comparison

Compare AGIO & BAK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AGIO
  • BAK
  • Stock Information
  • Founded
  • AGIO 2007
  • BAK 1972
  • Country
  • AGIO United States
  • BAK Brazil
  • Employees
  • AGIO N/A
  • BAK N/A
  • Industry
  • AGIO Biotechnology: Pharmaceutical Preparations
  • BAK Major Chemicals
  • Sector
  • AGIO Health Care
  • BAK Industrials
  • Exchange
  • AGIO Nasdaq
  • BAK Nasdaq
  • Market Cap
  • AGIO 1.4B
  • BAK 1.4B
  • IPO Year
  • AGIO 2013
  • BAK N/A
  • Fundamental
  • Price
  • AGIO $33.97
  • BAK $3.31
  • Analyst Decision
  • AGIO Buy
  • BAK Strong Buy
  • Analyst Count
  • AGIO 6
  • BAK 3
  • Target Price
  • AGIO $58.60
  • BAK $9.75
  • AVG Volume (30 Days)
  • AGIO 529.1K
  • BAK 777.6K
  • Earning Date
  • AGIO 07-31-2025
  • BAK 08-06-2025
  • Dividend Yield
  • AGIO N/A
  • BAK N/A
  • EPS Growth
  • AGIO N/A
  • BAK N/A
  • EPS
  • AGIO 11.45
  • BAK N/A
  • Revenue
  • AGIO $37,035,000.00
  • BAK $13,770,122,923.00
  • Revenue This Year
  • AGIO $22.30
  • BAK $18.11
  • Revenue Next Year
  • AGIO $219.19
  • BAK $7.32
  • P/E Ratio
  • AGIO $3.00
  • BAK N/A
  • Revenue Growth
  • AGIO 25.96
  • BAK 14.35
  • 52 Week Low
  • AGIO $23.42
  • BAK $2.85
  • 52 Week High
  • AGIO $62.58
  • BAK $7.71
  • Technical
  • Relative Strength Index (RSI)
  • AGIO 52.40
  • BAK 39.30
  • Support Level
  • AGIO $32.53
  • BAK $3.16
  • Resistance Level
  • AGIO $34.34
  • BAK $3.87
  • Average True Range (ATR)
  • AGIO 1.28
  • BAK 0.12
  • MACD
  • AGIO -0.31
  • BAK -0.04
  • Stochastic Oscillator
  • AGIO 20.98
  • BAK 20.42

About AGIO Agios Pharmaceuticals Inc.

Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.

About BAK Braskem SA ADR

Braskem SA manufactures and sells chemicals, petrochemicals, fuels, and utilities. The company's geographical segments include Brazil; the United States and Europe and Mexico. It derives a majority of its revenue from Brazil. It produces olefins, such as ethylene, polymer and chemical-grade propylene, butadiene, and butene-1; fuels, such as automotive gasoline, liquefied petroleum gas, or LPG, ethyl tertiary-butyl ether, or ETBE, and methyl tertiary-butyl ether, or MTBE; intermediates, such as cumene and others.

Share on Social Networks: